Robert M. Jotte, MD, PhD

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the optimal frequency of lung cancer screening.

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non